[1]孙文善.几种新型的中枢多巴胺转运蛋白显像剂[J].国际放射医学核医学杂志,2000,24(2):62-67.
　SUN Wen-shan.Several new imaging agents for central dopamine transporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(2):62-67.
点击复制

几种新型的中枢多巴胺转运蛋白显像剂(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
24
期数:
2000年第2期
页码:
62-67
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Several new imaging agents for central dopamine transporter
作者:
孙文善
200025 上海, 上海第二医科大学附属瑞金医院核医学科
Author(s):
SUN Wen-shan
Department of Nuclear Medicine, Shanghai Ruijin hospital, Shanghai Second Medical University, Shanghai 200025, China
关键词:
多巴胺转运蛋白显像剂; 帕金森病; 单光子发射计算机断层显像; 正电子发射计算机断层显像
Keywords:
dopamine transporter imaging agent; Parkinson’s disease; posihon emission computed tomography; single photon emission computed tomography
分类号:
R817.9
摘要:
中枢多巴胺转运蛋白显像剂123I-β-CIT(2β-carbomethoxy-3β-[4-iodophenyl]-tropane)在帕金森病诊断和鉴别诊断以及病情严重程度的评估的显像研究中已取得成功,但由于123I-β-CIT对多巴胺转运蛋白选择性较低,最佳显像时间在注射后20h,限制了其临床应用。近年来,人们又设计合成了几种新型的中枢多巴胺转运蛋白显像剂,使中枢多巴胺转运蛋白显像特性得到了明显的改善。
Abstract:
123I-β-CIT (2β-carbomethoxy-3β-[4-iodophenyl]-tropane), a promising agent for imaging central dopamine transporter, has been successfully used in clinical and differential diagnosis and assessment of the magnitude of degeneration of nigrastriatum in Parkinson’s disease.However, due to its poor selectivity for dopamine transporter and prolonged imaging intervel (usually 20h after injection), and therefore limits its clinical use. Several new imaging agents have been developed for dopamine transporter in recent years, and siginificantly improved the characterization for imaging dopamine transporter.

参考文献/References:

[1] 孙文善.中枢多巴胺转运蛋白显像剂123I-β-CIT研究进展[J].国外医学·放射医学核医学分册,1999, 23(2):49~51.
[2] Baldwin RM, Zea-ponce Y, Al-Tikrti MS, et al. Regional brain uptake and [123I]N-ω-fluoropropyll-2β-carbomethoxy-3β-(4-iodophenyl) nortropane esters in baboons[J]. Nucl Med Biol, 1995, 22:211~219.
[3] Booij J, Hemelaar JT, Speelman JD, et al. One day protocol for imaging of the nigrostristal dopaminergic pathway in Parkinson’s disease by [123I] FPCIT SPECT[J]. J Nucl Med,1999, 40:753~761.
[4] Tissingh G,Booij J,Bergmans P,et al.Iodin 3-123-N-ω-fluoropropyll-2β-carbomethoxy-3β-(4-iodophenyl) tropane SPECT in healthy controls and early-stage,drug-naive Parkinson’s diaeaea[J]. J Nucl Med, 1998, 39:1143~1148.
[5] Kuikka JT, Bergstrom KA, Ahonen A, et al. Comparsion of iodione-123 labelled 2β-carbomethoxy-3β-(4-iodopheny) tropane and 2β-earbomethoxy-3β-(4-iodopheny)-N-(3-fluoropropyl) nortropane for imaging of the dopamine of the dopamine transporter in the living human brain[J]. Eur J Nucl Med, 1995, 22:356~360.
[6] Seibyl JP, Marek K, Sheff K, et al. Iodione-123β-CIT and iodione-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients[J]. J Nucl Med,1998, 39:1500~1508.
[7] Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET[J]. J Nucl Med, 1998, 39:1521~1530.
[8] Madras BK, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:I. Dopamine transporter binding in primate brain[J]. Synapse, 1998, 29:93~104.
[9] Madras BK, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:Ⅱ.Dopamine transporter binding in primate brain[J]. Synapse, 1998, 29:105~115.
[10] Madras BK, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:Ⅲ.Dopamine transporter binding in primate brain[J]. Synapse, 1998, 29:116~127.
[11] Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson’s disease by SPECT with altropane:a selective ligand for dopamine transporters[J]. Synapse,1998, 29:128~141.
[12] Emond P,Garreau L,Chalon S,et al.Synthesis and ligand binding of nortropane derivatives:N-substituted 2β-carbomethoxy-3β-(4’-iodophenyl) nortropane and N-(3-iodoprop (2E) enyl)-2β-carbomethoxy-3β-(3’,4’-disubstituted phenyl) nortropane.New high-affinity and selective compounds for the dopamine transporter[J]. J Med Chem,1997, 40:1366~1372.
[13] Guilloteau D,Emond P,Baulieu JL,et al.Exploration of the dopamine transprter:in vitro and in vivo characterization of a high-affinity and high-specificity iodnated tropane derivative (E)-N-(3-iodoprop-2-enyl) 2β-carbomethoxy-3β-(4’-methylpheny) nortropane(PE2I)[J]. Nucl Med Biol, 1998, 25:331~337.
[14] Kuikka JT, Baulieu JL, Hitunen J, et al. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging[J]. Eur J Nucl Med, 1998, 25:531~534.
[15] Emond P, Chalon S, Garreau L, et al. A new iodinated tropane derivative (β-CDIT) for in vivo dopamine transporter exploration:comparison with β-CIT[J]. Synapse, 1997, 26:72~80.
[16] Laakso A, Bergman J, Haaparanta M, et al.[18F]-CFT ([18F]WIN35428), a radioligand to study the dopamine transporter with PET:characterization in human subjects[J]. Synapse, 1998, 28:244~250.
[17] Rinne JO, Bergman J, Ruottinen H, et al. Striatal uptake of a novel PET ligand,[18F]β-CFT, is reduced in early Parkinson’s disease[J]. Synapse, 1999, 31:119~124.
[18] Haaparanta M,Bergman J,Laakso A.[18F]-CFT ([18F] WIN35428),a radioligand to study the dopamine rtansporter with PET:Biodistribution in rats[J]. Synapse,1996, 23:321~327.
[19] Meegalla SK,Plossl K,Kung MP,et al.Specificity of dinsteremomers of [99mTc] TRODAT-1 as dopamine transporter imaging agents[J], J Med Chem, 1998, 41:428~436.
[20] Kung MP, Stevenson DA, Plossl MP, et al. Technetiuum-99m TRODAT-1:a novel technetium-99m complex as a dopamine transporter imaging agent[J]. Eur J Nucl Med, 1997, 24:372~380.
[21] Kung HF, Kim HJ, Kung MP, et al. Imaging of dopamine transporters in humans with technetium-99mTRODAT-l[J]. Eur J Nucl Med, 1996, 23:1527~1530.
[22] Mozley PD,Stubbs JB,Plossl K,et al.Biodistribution and dosimetry of T RODAT-1:a technetium-99m tropane for imaging dopamine transporters[J]. J Nucl Med, 1998, 39:2069~2076.
[23] Dresel SH, Kung MP, Huang X, et al. In vivo imaging of serotonin transporters with [99mTc] TRODAT-1 in nonhuman primates[J]. Eur J Nucl Med, 1999, 26:342~347.
[24] Meltzer PC, Blundell P, Jones AG, et al. A technetium-99m tropane SPECT imaging agent which targets the dopamine transporters in primate brain[J]. J Med Chem, 1997, 40:1835~1844.

相似文献/References:

[1]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
　Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[2]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
　Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[3]闫卫红.Raclopride在帕金森病PET中的应用[J].国际放射医学核医学杂志,2005,29(1):27.
　YAN Wei-hong.Application of raclopride PET in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):27.
[4]董爱生,田建明.PET、SPECT及MRS在帕金森病诊断中的应用[J].国际放射医学核医学杂志,2005,29(6):244.
　DONG Ai-sheng,TIAN Jian-ming.The application of PET、SPECT and MRS in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):244.
[5]谭海波,刘兴党.PET在神经干细胞移植治疗帕金森病研究中的进展[J].国际放射医学核医学杂志,2004,28(6):253.
　TAN Hai-bo,LIU Xing-dang.Progress of PET imaging in the study of neural stem cell transplantation treating Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):253.
[6]田季雨.PET在帕金森病病理机制研究中的应用近况[J].国际放射医学核医学杂志,2003,27(2):53.
　TIAN Ji-yu.Recent application of PET in the pathological mechanisms of PD[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(2):53.
[7]张海琴.中枢多巴胺转运蛋白显像剂99TcmTRODAT-1[J].国际放射医学核医学杂志,2001,25(3):100.
　ZHANG Hai-qin.99Tcm-TRODAT-1: the central dopamine transporter imaging agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):100.
[8]左传涛.18F—多巴PET在帕金森病中的应用[J].国际放射医学核医学杂志,2000,24(1):4.
　ZUO Chuan-tao.The Applications of 18F-DOPA PET in Parkinson’s Disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(2):4.
[9]邓玮玮,张春银.放射性核素显像在帕金森病鉴别诊断中的应用[J].国际放射医学核医学杂志,2017,41(2):132.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
　Deng Weiwei,Zhang Chunyin.Application of radionuclide imaging on differential diagnosis of Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):132.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
[10]于江,段玉清,毕常芬,等.多巴胺转运体PET显像剂11C-Altropane的研究进展[J].国际放射医学核医学杂志,2018,(1):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]
　Yu Jiang,Duan Yuqing,Bi Changfen,et al.Progress of dopamine transporter PET imaging agent 11C-Altropane[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]

备注/Memo

备注/Memo:
收稿日期:1999-12-06。
作者简介:孙文善(1969-),男,山东阳谷人,上海第二医科大学附属瑞金医院核医学科医学博士,主要从事神经递质转运蛋白研究。
更新日期/Last Update: 1900-01-01